trial fibrillation (AF) occurs in 0.4% of the general population, increasing to 5% in those over 65 years of age, and it is the most common arrhythmia, increasing cardiac morbidity and mortality. 1 AF is related to the structural and functional remodeling of the left atrium (LA) and ventricle (LV) because of persistent arrhythmia. 2, 3 To restore sinus rhythm (SR), both electrical cardioversion (ECV) and radiofrequency (RF) catheter ablation (ABL) have proven to be effective treatment modalities for patients with AF. 4 Reverse morphological remodeling of the LA and improvement in LV diastolic and systolic functions after restoration of SR by either treatment modality have been demonstrated. 5 However, differences in the degree and the time course of functional reverse remodeling of the LA according to the each treatment modality have not been investigated. The objective of this study was to investigate the morphological and functional changes of the LA and LV in patients with sustained SR either after ABL or ECV.
Methods

Study Population
Sixty-three AF patients who had maintained SR for 3 months after either ECV (n=30, M:F 24:6, mean age 58.6± 9.3 years) or ABL (n=33, M:F 27:6, mean age 55.9±10.2 years) were included. Patients who underwent re-do ablation were excluded. Paroxysmal AF (PAF) was defined as the occurrence of 2 or more episodes of AF during the previous 12 months, typically lasting fewer than 7 days and terminating spontaneously. Persistent AF (PeAF) was defined as AF episodes lasting more than 7 days typically requiring cardioversion for restoration of SR. 6 The 29 of 30 patients had PeAF in the ECV group and 21 of 33 patients had PAF in the ABL group. All clinical information was obtained from medical records, and all patients completed a written informed consent form to participate in the study.
ECV
ECV was performed if LA thrombi were not seen on transesophageal echocardiography. Direct current (DC) shock was delivered during sedation induced with intravenous midazolam (0.04 mg/kg) and pentothal sodium (1.5 mg/kg). One defibrillator pad with a 10-cm diameter was placed in the second intercostal space on the right side parasternally, the other was placed in a left-sided lateral position along the midaxillary line. The cardioversion procedure started with 70 J or 100 J of stored energy followed by 125 J and 150 J until the restoration of SR or failure to convert. Continuous electrocardiographic (ECG) monitoring was performed for several hours after the procedure to assess the maintenance of SR.
RF ABL
Antiarrhythmic drugs were discontinued for a period corresponding to at least 5 half-lives of each of the medications taken. Amiodarone was discontinued for at least 4 weeks. Proper anticoagulation was maintained with warfarin or heparin. Transesophageal echocardiography was performed to exclude the presence of atrial thrombus. After informed consent was given, we conducted the ABL procedure using 3-dimensional (D) mapping (NavX, St Jude Medical Inc, Minneapolis, MN, USA) in all patients. Intracardiac electrogram was recorded using a Prucka CardioLab™ Electrophysiology system (General Electric Medical Systems, Inc, Milwaukee, WI, USA). After double transseptal punctures, selective pulmonary vein (PV) angiography was performed. PVs were mapped with a 20-pole circular Lasso catheter (Biosense Webster Inc, Diamond Bar, CA, USA) and ablated with a 4-mm open irrigated-tip catheter (20-30 ml/min; Celsius, Johnson & Johnson Inc, Diamond Bar, CA, USA), and RF energy was delivered through a Stockert generator (Biosense Webster Inc, Diamond Bar, CA, USA) in a temperature-controlled mode and limited to 50°C using a maximal power of 35 W and duration of 20-60 s. The procedure endpoint was the completion of the circumferential antral ablation and electrical isolation of the PV. Carvotricuspid isthmus ablation was performed in patients with PeAF to achieve complete isthmus block. Additional linear lines were performed in case of persisting arrhythmia after electrical isolation of PVs and consisted of left mitral isthmus and/or LA roof ablation. All patients received heparin intravenously, maintaining the activated clotting time between 350 and 400 s to avoid thromboembolic complications. The patients were followed up at 1-2 weeks after ablation, and then every 1-3 months with ECG or Holter monitor recordings.
Echocardiographic Studies
Each patient underwent 4 complete M-mode, 2-D, and Doppler echocardiography sessions using a Sonos 7500 system (Hewlett-Packard) with a 2.5-MHz transducer. The echocardiography protocol was as follows. The first examination was immediately before ABL or ECV, and follow-up studies were was scheduled for 1 week, 1 month, and 3 months after restoration of SR. All echocardiographic images were stored on videotape and analyzed offline with a customized software package in the Sonos 7500 system. Transesophageal echocardiography was also performed in all cases as a screening test before the procedure. LA anterior -posterior, superior -inferior, and medial -lateral diameters were measured on the parasternal long axis and apical 4-chamber views at end-systole, according to the American Society of Echocardiography (ASE) guideline. 7, 8 The LA end-systolic volume (LAESV, the maximum LA volume during ventricular systole) and LA end-diastolic volume (LAEDV, the minimum LA volume during ventricular diastole) were assessed by the biplane area -length method from the apical 4-and 2-chamber views (LA volum=0.85×[4-chamber area ×2-chamber area]/common length). 9, 10 The measurements of the LA dimensions and volumes were acquired from 3 consecutive beats in those presenting in SR, and from 8-10 beats for those in AF, and subsequently averaged. LV volume and ejection fraction (EF) were assessed by Simpson's method. Transmitral pulsed Doppler was recorded from the apical 4-chamber view, with the sample volume positioned between the tips of the mitral leaflets. 11 Peak early filling (E) and late filling (A) velocities were recorded. The E/A ratio was calculated, and the E-wave deceleration time was measured. Pulsed TDI measurements of mitral annulus motion were performed in the apical 4-chamber view, with a 10-mm sample volume placed at the septal aspect of the mitral annulus. Early (E') and late (A') diastolic peak velocities were recorded. 12 
Statistical Analysis
All value are expressed as mean ± SD. Differences between groups were examined with a paired Student's t-test. The statistical significance of serial changes in the echocardiographic parameters after the procedure was determined by analysis of variance for repeated measures ANOVA. The effect of drugs on these parameters between both groups was examined by 2-way layout ANOVA. The correlation between the size of the ablation region and the LA function was assessed by multivariate regression analysis. A value of p<0.05 was considered statistically significant. Data were analyzed using SPSS (version 12.0; Chicago, IL, USA).
Results
Clinical Characteristics
Clinical characteristics of the subjects in the ECV and ABL groups are shown in Table 1 . The 2 treatment groups were well balanced with respect to baseline age and sex. Study population was heterogeneous in the type of AF between groups. PeAF was more common in the ECV group than in the ABL group (97% vs 36%, p<0.001). The duration of AF, including PAF and PeAF, was longer in the ABL group than in the ECV group (ECV group: 21.2±17.8 months vs ABL group: 62.6±47.0 months, p<0.001). Before ECV or ABL, the LVEF fraction was lower in the ECV group than in the ABL group (47.7±9.7% vs 53.1±6.0%, p=0.009). The number of patients using antiarrhythmic drugs was similar in both groups, but amiodarone was the most commonly used drug in the ECV group, and either amiodarone or propafenone in the ABL group (Table 1) . Patients with hypertension were more frequent in the ECV group than in the ABL group (p=0.008). In the ABL group, 1 patient underwent mitral annuloplasty and 1 patient had moderate mitral regurgitation. The use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin-receptor blockers (ARB) was more frequent in the ECV group than in the ABL group (60.0% vs 24.2%, p=0.004) ( Table 1) .
LA Dimensions and Volumes
At baseline, the LA dimensions and volumes were higher in the ECV group than those of the ABL group. After ABL or ECV, LA dimensions (anteroposterior, mediolateral, and superoinferior diameters) in both groups decreased significantly in a progressively linear trend over time in each echocardiographic view (Table 2 ). LAESV and LAEDV decreased significantly 3 months after ECV and ABL compared with baseline (p=0.001 and <0.001, respectively). The LA dimensions and volumes were also higher in the ECV group than those of the ABL group throughout the follow-up period up to 3 months after each procedure.
Systolic Function of LV and LA
In the ECV group, the LVEF was lower at baseline, but it improved (from 47.7±9.7% at baseline to 55.3±8.7% at 3 months; p<0.001) and reached the level of the ABL group in the 3-month follow-up period (Table 3 ). The LA EF during the 3-month follow-up, as compared with that at baseline, improved significantly only in the ECV group (31.4±9.5 to 39.5±9.1% in ECV group, p=0.004 vs 31.8± 12.8 to 30.9±10.0% in ABL group, p=0.640).
Doppler Parameters: Changes of Mitral Inflow Velocity
In the ECV group, the E velocity decreased gradually from 70.1±19.4 cm/s at 1 week after cardioversion to 56.5± Fig 1) .
Tissue Doppler Parameters: Changes in the Mitral Annulus Velocity
The E' velocity in the both groups did not change significantly after cardioversion; however, the A' velocity increased from 1 week to 3 month after ECV (6.4±1.5 to 7.1±1.9 cm/s, p=0.012). In the ABL group, A' velocity decreased from 9.7±1.9 at baseline to 6.0±2.1 cm/s at 1 week after ablation (p=0.007), and increased to 7.6±1.6 cm/s through 3 months (p=0.009). However, the A' height at 3 months was lower than that at baseline (Table 3, Fig 1) .
Ablation Lesion and LA function
The mean number of RF energy deliveries during ABL was 142.7±55.8 times. Eighteen patients (54.5%) underwent additional linear ablation, including carvotricuspid isthmus (n=7, 51.5%), LA roof line (n=9, 27.3%), or left mitral isthmus (n=6, 18.2%). The size of the ablation lesion combined with number of the RF energy deliveries and additional linear ablation lesion did not significantly reduce A and A' velocities. Additional linear lesion did not significantly affect the reduction in LA function. However, the number of RF energy deliveries significantly correlated with the reduction in A' velocity from baseline to 1 week after ABL (p=0.031).
Effects of Postprocedural Antiarrhythmic Drugs and ACEIs or ARBs
In the ablation group, 9 of 33 patients (27.3%) were prescribed antiarrhythmic drugs during 3 months after ABL [amiodarone (9.1%, n=3/33), flecainide (12.1%, n=4/33), or both drugs (6.1%, n=2/33)]. However, because most patients in the cardioversion group had PeAF, antiarrhythmic drugs were prescribed to all patients to maintain SR after cardioversion of AF [amiodarone (86.7%, 26/30) and flecainide (13.3%, 4/30)]. 13 All patients who had received ACEIs or ARBs were prescribed these drugs during the 3 months after ABL (n=8/33) or ECV (n=18/30). In both groups, the use of ACEIs or ARBs did not affect the change in LA size and function, including A and A' velocities, reflecting reverse remodeling of the LA after the procedure (p>0.05 for all variables).
Subgroup Analysis
Because the baseline LA dimension was larger in the ECV 
Fig 1. Changes in mitral inflow velocity (Upper panels) and mitral annulus velocity (Lower panels). Although the A'
velocity increased linearly over time in both groups, the E and A velocity increased in a linear trend over time only in the electrical cardioversion (ECV) group. In catheter ablation (ABL) group, the A velocity decreased within 1 week and increased from 1 week through 3 months linearly, but did not recover to the baseline A' velocity. *p<0.05 at 3 months vs at baseline in ABL group; **p<0.05, repeated measures ANOVA from 1 week to 3 months; † † p>0.05, repeated measures ANOVA from 1 week to 3 months.
group than in the ABL group (LA anteroposterior diameter: 45.4±4.6 vs 41.0±5.4 mm, p=0.001), subgroup analysis was done in patients with similarly sized LAs. In patients with an LA anteroposterior diameter ranging from 40.0 mm to 49.0 mm, the LA size and volume decreased significantly after the procedure in both groups (p<0.05 for all variables; Table 4 ). The A and A' velocities increased with a linear trend after cardioversion (A velocity: 40.1±14.2 to 55.3± 13.7 cm/s, p=0.001; A' velocity: 6.2±1.6 to 7.2±2.0 cm/s, p<0.001). The A velocity increased from 1 week through 3 months after ablation, but with no statistical significance. The A' velocity in the ABL group decreased within 1 week after the procedure (10.5±1.5 at baseline to 4.6±1.1 cm/s at 1 week, p=0.042), and then increased from 1 week through 3 months (4.6±1.1 at 1 week to 7.2±1.7 cm/s at 3 months, p=0.024), but did not recover to the baseline level (Fig 2) .
In the subgroup analysis of PeAF patients with an LA anteroposterior diameter of 40-49 mm (n=21 in ECV group vs n=8 in ABL group), both A and A' velocities increased significantly only in the ECV group (Fig 2) .
Discussion
Main Findings
This study was a retrospective echocardiographic evaluation for the recovery process of atrial remodeling, including the morphological and functional changes of LA in patients with sustained SR after RF ABL or ECV. This investigation confirms previous observations of the reverse remodeling effects on LA size and volume after restoration of SR from Tables 1,2 . AF. 6, 14, 15 The LA dimensions started decreasing within less than 1 month, and during the 3 months of follow-up after restoration of SR by ABL or DC shock, the LA dimensions decreased significantly and progressively. The morphological and functional changes in the LA after RF ABL were shown to be different from those occurring after ECV in the present study. We observed an improvement in LA function associated with an increase in late mitral inflow and late diastolic mitral annulus motion after cardioversion, but not after ABL. The late diastolic mitral annulus motion decreased within 1 week after ablation for AF, and increased from 1 week through 3 months but the A' velocity did not recover to the baseline level.
LA Remodeling of AF
AF is associated with ventricular and atrial remodeling, and deterioration in both LV diastolic and systolic function, but its pathophysiology remains unclear. Three cascades of electrical, contractile, and structural remodeling have been proposed, and the positive feed-back mechanism between electrical remodeling and AF is well established, whereas the proposed cascades of contractile and structural remodeling are still hypothetical. 2 Downregulation of the L-type Ca 2+ channel is considered to be the primary cause for electrical and contractile remodeling. 2 The electroanatomical substrate of AF may consist of dilated atria allowing small intra-atrial circuits because of a reduction in wavelength and increased non-uniform anisotrophy. 2 Several recent studies have shown echocardiographic abnormalities in patients with AF. Jaïs et al observed in 28 lone AF patients a significant increase in longitudinal LA diameter in the apical 4-chamber view and an increase in filling pressure during cardiac catheterization. 16 Thamilarasan et al reported a significant increase in LA dimensions in 24 lone PAF patients, LV diastolic dysfunction assessed by TDI, and a significant decrease in LVEF. 17 In our study, the LA was dilated at baseline, and its size was larger in AF patients who underwent ECV than in those who underwent ablation. LA mechanical function was relatively preserved in both groups before the procedure.
Reverse Remodeling After Restoration of SR for AF
This study showed a significant and sequential decrease in LA dilation after ablation or cardioversion for AF. These results are in agreement with previous reports that both cardioversion and ABL are associated with a reduction in LA size. 5, 18 Atrial remodeling with SR may decrease, with a resultant improvement in effective atrial contractile function. In the present study, LA function improved from 1 week through 3 months after sinus conversion in patients with AF, and in patients with ablation, it decreased within 1 week. This reduction in LA function after ABL could result from atrial splitting by scarring and loss of atrial myocardial mass from ablation to the atrium, as previously demonstrated in a canine model. 19 The scarring may caused splinting and prevent further dilation of the LA. Because ABL may lead to atrial splitting by scarring, we thought the reduction in late mitral inflow and the late diastolic mitral annulus motion during the 1 week after ABL was affected by the number of RF energy deliveries and additional linear ablation. In our data, only the number of the RF energy deliveries was significantly associated with a reduction in the A' velocity from baseline to 1 week after ablation. Reant et al showed significant improvement of diastolic function with an increase in lateral early diastolic peak velocity of 29% in PAF patients and 46% in chronic AF patients. 5 The peak velocity of early relaxation (E' velocity) has been developed as a marker of diastolic function that is relatively preload independent. 20 Although decreased peak A velocity on transmitral flow may be observed in atrial dysfunction, transmitral flow patterns are influenced by LV relaxation and afterload. 21 The A' velocity, which estimates intrinsic myocardial longitudinal contraction velocity, may therefore be a more robust marker of atrial function. We measured only the septal A' velocity because no significant difference was demonstrated previously between septal and lateral peak A' velocity. 22 
Study Limitations
This was a nonrandomized and retrospective study, and there were significant differences in the type (paroxysmal vs persistent) and duration of AF between the ablation and cardioversion group. In the cardioversion group, LA size was significantly larger and LVEF less than in the ablation group, and the AF duration was longer after ablation than after cardioversion. Though subgroup analysis demonstrated no significant differences between groups in relation to atrial size or function, the numbers in each subgroup were relatively small. Second, it is possible that antiarrhythmic drugs during the 3 months after the procedures may have influenced the interpretation of the results. Maintenance of SR by these medications may result in potential improvement of atrial function and size. Furthermore, because amiodarone blocks the channels that are upregulated by remodeling, 23 such as Ikl, Ikach and Iks, 24, 25 or by hypertonicity of the sympathetic nervous system, it is thought that its pharmacological action is well suited to treating patients with long-standing persistent tachyarrhythmia. 13 Third, the ECV group included a much higher percentage of those who had hypertension and had more usage of ACEIs or ARBs than the ABL group, and these medications are likely to have had salutary effects on LA function and remodeling. 26 However, in our data, receiving ACEIs or ARBs did not significantly influence the reverse remodeling of the LA after ABL and ECV. The other limitation was that there was no baseline assessment of Doppler and tissue Doppler parameters because of the difficulty in taking measurements in patients with PeAF before the procedures.
Clinical Implications
The LA dysfunction induced by atrial stunning after DC shock may predispose the patient to thrombus formation and thromboembolic events. 27 Because normal atrial contraction is believed to lag behind conversion to SR and atrial mechanical dysfunction may exist for up to a few weeks, 3 patients undergoing cardioversion are often anticoagulated for a prolonged period. LA RF ablation results in SR maintenance for a majority of patients with PAF and chronic AF, [28] [29] [30] thereby potentially reducing the risk of thromboembolism. However, LA RF ABL itself reduces LA transport function by up to 30%, 31 which may predispose patients to thromboembolism even in the setting of SR. Therefore, patients over 65 years of age or who have a history of stroke are often maintained on warfarin, even when there is no evidence of recurrent AF. A recent study reported that the risk of post-ablation thromboembolism in patients who undergo LA RF ablation for PAF or chronic AF is 1.2%, with the highest period of risk being the first 2 weeks after ablation. 32 This emphasizes the importance of aggressive anticoagulation during the first few weeks after ablation. The results of our study show that LA function decreases in the early period after ablation and increases from 1 week to 3 months after ablation, but there was no statistical significance in the observed linear trend. Because the functional remodeling of LA did not recover to the baseline level at 3 months after ablation, more meticulous anticoagulation therapy should be considered for these patients.
Conclusion
Both RF ABL and ECV are effective procedures for restoring SR in AF patients. This observation demonstrates that reverse remodeling of the LA occurs in patients undergoing both successful ablation and cardioversion for AF. Although functional remodeling of LA develops from an early period in patients with sinus conversion after DC shock, the LA function decreases within 1 week after ablation and then tends to improve through 3 months. Though the difference in the mechanisms remains unclear, these results suggest that anticoagulation may be needed more after ablation than after cardioversion. Furthermore, assessment of LA and LV function with new echocardiographic parameters will be required to determine the timing of functional reverse remodeling in association with adequate anticoagulation for the prevention of thromboembolism in AF patients after ablation and cardioversion.
